5.39
-0.01 (-0.19%)
| Penutupan Terdahulu | 5.40 |
| Buka | 5.42 |
| Jumlah Dagangan | 1,012,589 |
| Purata Dagangan (3B) | 1,222,433 |
| Modal Pasaran | 1,213,607,040 |
| Harga / Pendapatan (P/E TTM) | 5.80 |
| Harga / Pendapatan (P/E Ke hadapan) | 5.24 |
| Harga / Jualan (P/S) | 2.00 |
| Harga / Buku (P/B) | 1.62 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Aug 2025 |
| Margin Keuntungan | 34.50% |
| Margin Operasi (TTM) | -6,128.33% |
| EPS Cair (TTM) | 0.930 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -92.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.78% |
| Nisbah Semasa (MRQ) | 7.65 |
| Aliran Tunai Operasi (OCF TTM) | 157.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 92.39 M |
| Pulangan Atas Aset (ROA TTM) | 19.92% |
| Pulangan Atas Ekuiti (ROE TTM) | 33.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | CureVac N.V. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 0.5 |
| Purata | -1.00 |
|
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 57.37% |
| % Dimiliki oleh Institusi | 4.70% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gates Foundation | 30 Sep 2024 | 1,568,866 |
| Freestone Capital Holdings, Llc | 31 Mar 2025 | 144,073 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (JMP Securities, 85.53%) | Beli |
| Median | 5.50 (2.04%) | |
| Rendah | 5.00 (Jefferies, -7.24%) | Pegang |
| Purata | 6.83 (26.72%) | |
| Jumlah | 1 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 5.14 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 26 Jun 2025 | 5.50 (2.04%) | Pegang | 5.40 |
| 30 Apr 2025 | 12.00 (122.63%) | Beli | 3.55 | |
| Jefferies | 13 Jun 2025 | 5.00 (-7.24%) | Pegang | 5.57 |
| JMP Securities | 28 May 2025 | 10.00 (85.53%) | Beli | 4.44 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 24 Jun 2025 | Pengumuman | CureVac Announces Voting Results of General Meeting |
| 20 May 2025 | Pengumuman | CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates |
| 15 May 2025 | Pengumuman | CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |